| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328321 | Acta Haematologica Polonica | 2014 | 9 Pages |
Abstract
The last ASH conference 2012 provided further reports confirming the efficacy of bortezomib in the treatment of newly diagnosed myeloma, both in younger patients eligible for stem cell transplantation, and elderly who are not candidates for this procedure. Moreover, a few reports suggested that neurotoxicity associated with bortezomib might be significantly reduced with subcutaneous administration.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Artur Jurczyszyn, Norbert GrzÄ
Åko, Jan Maciej Zaucha,